Literature DB >> 12849864

Enzymatic diagnostic test for Muscle-Eye-Brain type congenital muscular dystrophy using commercially available reagents.

Wenli Zhang1, Jiri Vajsar, Pinjiang Cao, Galen Breningstall, Charlotta Diesen, William Dobyns, Ralph Herrmann, Anna-Elina Lehesjoki, Alice Steinbrecher, Beril Talim, Tatsushi Toda, Haluk Topaloglu, Thomas Voit, Harry Schachter.   

Abstract

OBJECTIVES: Mutations disrupting the interaction of extra-cellular ligands and alpha-dystroglycan are responsible for an etiologically heterogeneous group of autosomal recessive congenital muscular dystrophies (CMD) that can have associated brain and eye abnormalities. The objective is to develop a diagnostic test for one of these CMDs, Muscle-Eye-Brain disease (MEB), due to mutations in the gene encoding Protein O-Mannosyl beta-1,2-N-acetylglucosaminyltransferase 1 (POMGnT1). DESIGN AND METHODS: POMGnT1 enzyme activity was determined in extracts of muscle biopsies from four MEB patients and various controls using commercially available reagents.
RESULTS: All four MEB muscle samples showed a highly significant decrease in POMGnT1 activity relative to controls.
CONCLUSIONS: The assay of POMGnT1 activity in MEB muscle provides a rapid and relatively simple diagnostic test for this disease. CMDs associated with brain malformations such as MEB, WWS and FCMD are heterogenous in clinical presentation and on radiologic examination, suggesting that POMGnT1 assays of muscle biopsies should be used as a screening procedure for MEB in all CMD patients associated with brain malformations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12849864     DOI: 10.1016/s0009-9120(03)00036-5

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  11 in total

1.  Long-term survival in a patient with muscle-eye-brain disease.

Authors:  Raffaele Falsaperla; Leandra Giunta; Riccardo Lubrano; Rosario Foti; Giovanna Vitaliti
Journal:  Neurol Sci       Date:  2015-07-08       Impact factor: 3.307

Review 2.  Mechanisms of disease: congenital muscular dystrophies-glycosylation takes center stage.

Authors:  Paul T Martin
Journal:  Nat Clin Pract Neurol       Date:  2006-04

Review 3.  The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis.

Authors:  Motoi Kanagawa; Tatsushi Toda
Journal:  J Hum Genet       Date:  2006-09-13       Impact factor: 3.172

4.  Endogenous glucuronyltransferase activity of LARGE or LARGE2 required for functional modification of α-dystroglycan in cells and tissues.

Authors:  Kei-ichiro Inamori; Tobias Willer; Yuji Hara; David Venzke; Mary E Anderson; Nigel F Clarke; Pascale Guicheney; Carsten G Bönnemann; Steven A Moore; Kevin P Campbell
Journal:  J Biol Chem       Date:  2014-08-19       Impact factor: 5.157

Review 5.  The dystroglycanopathies: the new disorders of O-linked glycosylation.

Authors:  Paul T Martin
Journal:  Semin Pediatr Neurol       Date:  2005-09       Impact factor: 1.636

6.  Novel POMGnT1 mutations cause muscle-eye-brain disease in Chinese patients.

Authors:  Hui Jiao; Hiroshi Manya; Shuo Wang; Yanzhi Zhang; Xiaoqing Li; Jiangxi Xiao; Yanling Yang; Kazuhiro Kobayashi; Tatsushi Toda; Tamao Endo; Xiru Wu; Hui Xiong
Journal:  Mol Genet Genomics       Date:  2013-05-21       Impact factor: 3.291

7.  Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy.

Authors:  Aaron M Beedle; Amy J Turner; Yoshiaki Saito; John D Lueck; Steven J Foltz; Marisa J Fortunato; Patricia M Nienaber; Kevin P Campbell
Journal:  J Clin Invest       Date:  2012-08-27       Impact factor: 14.808

8.  Novel POMGnT1 mutations define broader phenotypic spectrum of muscle-eye-brain disease.

Authors:  Ute Hehr; Goekhan Uyanik; Claudia Gross; Maggie C Walter; Axel Bohring; Monika Cohen; Barbara Oehl-Jaschkowitz; Lynne M Bird; Ghiat M Shamdeen; Ulrich Bogdahn; Gerhard Schuierer; Haluk Topaloglu; Ludwig Aigner; Hanns Lochmüller; Jürgen Winkler
Journal:  Neurogenetics       Date:  2007-09-29       Impact factor: 2.660

Review 9.  Congenital muscular dystrophies involving the O-mannose pathway.

Authors:  Paul T Martin
Journal:  Curr Mol Med       Date:  2007-06       Impact factor: 2.222

Review 10.  Muscular dystrophies due to defective glycosylation of dystroglycan.

Authors:  F Muntoni; M Brockington; C Godfrey; M Ackroyd; S Robb; A Manzur; M Kinali; E Mercuri; M Kaluarachchi; L Feng; C Jimenez-Mallebrera; E Clement; S Torelli; C A Sewry; S C Brown
Journal:  Acta Myol       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.